Halozyme Therapeutics Inc (HALO)

[friendofthedevil]

Define now

Hi Fritz,

Whenever I see something like this SEC doc, I wonder about timing. The "trigger date" is 12/31 and I'm aware some purchases by 5 or 10 percent owners have a trigger date that is "end of the year." The ph2 data came out afterward so this can't be taken as a sign of confidence in that.

All my biotechs are suffering these days. it seems Halozyme will drift with the market until 303 results. There may be a momentary bump if MabThera gains US approval or if there is a development with US Herceptin but 303 is the only thing, IMO, that is likely to move the needle permanently.

Regarding Trump's negative effect on biotech, it seems all wrong headed. Even if he could do the things he says, like put pressure on US drug prices and penalize ex-US aspects of the pharma business, the argument should be that would only spur pharma into more innovation and to buy US biotech companies. Whatever discount you want to try to calculate from eventual drug price to current biotech valuation can't amount to much compared to pharma's eventual need to repatriate, merge and acquire. Unless this is simply a sale of risk assets, it seems the ETF tail is wagging the dog and the ETF money is as dumb as can be.

If anyone has a link to a good article explaining the Trump effect on biotech, I'd love to read it. Thanks.